Overview of Ipsen's Inaugural Bond Issuance
Ipsen, a leading global biopharmaceutical company, has made a significant move by issuing its inaugural Rated Public Bond amounting to €500 million. This bond comes with a coupon rate of 3.875% and is set to mature in March 2032. The issuance reflects Ipsen's strong credit profile following the receipt of Investment Grade ratings from both S&P and Moody's, which assigned a rating of BBB- and Baa3, respectively, both with stable outlooks.
Investor Reception and Oversubscription
The bond offering was met with enthusiastic response from investors. It was largely oversubscribed, indicating solid demand from a diverse range of institutional investors. This appetite for Ipsen's bond is a testament to the confidence in the company's long-term growth strategies and financial stability.
Comments from Management
Aymeric Le Chatelier, the Executive Vice President and CFO of Ipsen, expressed satisfaction with the bond issuance outcome. He articulated that this successful bond launch not only signals investor confidence in Ipsen's investment-grade status but also emphasizes the company's commitment to sustained growth. He noted that the funds raised through this bond would support Ipsen's growth ambitions, driven by both its rich internal pipeline and innovations sourced externally.
Refinancing Plans and Debt Management
This bond issuance is a critical element of Ipsen’s refinancing strategy. Earlier this month, the company renewed its €1.5 billion syndicated Revolving Credit Facility for five years, with options for two one-year extensions. This extension significantly strengthens Ipsen's debt maturity profile, allowing for increased financial flexibility moving forward.
About Ipsen and Its Global Presence
Founded with a focus on delivering transformative medicines, Ipsen has established itself in key therapeutic areas including Oncology, Rare Disease, and Neuroscience. The company leverages nearly 100 years of development experience and maintains global hubs in the U.S., France, and the U.K. Its operations extend to over 40 countries, enabling Ipsen to provide innovative medicines in more than 80 markets worldwide.
Investor Relations
For investors looking to connect with Ipsen, the company provides contact information for its investor relations team. Alina Levchuk can be reached at +41 79 572 8712, while Nicolas Bogler is available at +33 6 52 19 98 92. Both are ready to address any inquiries regarding the company's financial status and future strategies.
Media Inquiries
The media can contact Sally Bain at +1 857 320 0517 or Anne Liontas at +33 7 67 34 72 96 for any press-related questions about Ipsen’s initiatives and announcements. Their expertise will provide the necessary insights into Ipsen's market actions and future developments.
Frequently Asked Questions
What was the amount of Ipsen's inaugural bond issuance?
The inaugural bond issuance by Ipsen amounted to €500 million with a coupon rate of 3.875%.
Who rated Ipsen’s bonds, and what were the ratings?
Both S&P and Moody's assigned Ipsen an Investment Grade rating, BBB- and Baa3 respectively, with stable outlooks.
What does Ipsen hope to achieve with the bond proceeds?
Ipsen aims to utilize the proceeds to bolster its financial flexibility and support ongoing growth initiatives driven by internal and external innovations.
What is Ipsen's focus as a biopharmaceutical company?
Ipsen focuses on delivering transformative medicines in Oncology, Rare Disease, and Neuroscience while leveraging nearly 100 years of experience.
How can investors contact Ipsen?
Investors can reach out to Alina Levchuk at +41 79 572 8712 or Nicolas Bogler at +33 6 52 19 98 92 for inquiries related to the company's performance.
